https://nerlynxhcp.com/component---src-pages-isi-tsx-a3c019a76dd14790a009.js/

1"use strict";(self.webpackChunkspl004=self.webpackChunkspl004||[]).push([[548],{3078:function(A,i,t){t.r(i);var o=t(8479),a=t(7604),e=t(5126),n=t(2445);var s={name:"clvnq5",styles:"padding-top:60px;padding-bottom:60px;@media (min-width: 768px){padding-top:64px;padding-bottom:64px;}"},I={name:"1o799l6",styles:"margin-bottom:24px;margin-top:0px;font-family:var(--font-primary);font-weight:700;text-transform:uppercase;line-height:30px;font-size:24px"},g={name:"1bakwvp",styles:"margin-bottom:32px;font-size:18px;transition-property:all;transition-timing-function:cubic-bezier(0.4, 0, 0.2, 1);transition-duration:300ms;@media (min-width: 768px){margin-bottom:48px;}"},l={name:"1p5cpq7",styles:"margin-bottom:24px !important"},r={name:"1p5cpq7",styles:"margin-bottom:24px !important"},C={name:"1b5xezq",styles:"margin-bottom:24px;margin-top:0px;font-family:var(--font-primary);font-weight:700;line-height:30px;font-size:24px"},E={name:"50zrmy",styles:"text-transform:uppercase"},p={name:"il4vqu",styles:"margin-bottom:32px;font-size:18px;line-height:1.375;transition-property:all;transition-timing-function:cubic-bezier(0.4, 0, 0.2, 1);transition-duration:300ms;@media (min-width: 768px){margin-bottom:48px;}"},Q={name:"1p5cpq7",styles:"margin-bottom:24px !important"},S={name:"1tz49se",styles:"margin-bottom:32px;font-size:24px;@media (min-width: 768px){margin-bottom:48px;}"},m={name:"1o799l6",styles:"margin-bottom:24px;margin-top:0px;font-family:var(--font-primary);font-weight:700;text-transform:uppercase;line-height:30px;font-size:24px"},q={name:"1j389vi",styles:"font-weight:700"},K={name:"il4vqu",styles:"margin-bottom:32px;font-size:18px;line-height:1.375;transition-property:all;transition-timing-function:cubic-bezier(0.4, 0, 0.2, 1);transition-duration:300ms;@media (min-width: 768px){margin-bottom:48px;}"},F={name:"1p5cpq7",styles:"margin-bottom:24px !important"},c={name:"1p5cpq7",styles:"margin-bottom:24px !important"},U={name:"1p5cpq7",styles:"margin-bottom:24px !important"},B={name:"1p5cpq7",styles:"margin-bottom:24px !important"},J={name:"1p5cpq7",styles:"margin-bottom:24px !important"},h={name:"1o799l6",styles:"margin-bottom:24px;margin-top:0px;font-family:var(--font-primary);font-weight:700;text-transform:uppercase;line-height:30px;font-size:24px"},d={name:"il4vqu",styles:"margin-bottom:32px;font-size:18px;line-height:1.375;transition-property:all;transition-timing-function:cubic-bezier(0.4, 0, 0.2, 1);transition-duration:300ms;@media (min-width: 768px){margin-bottom:48px;}"},k={name:"w3f3w7",styles:"margin-bottom:32px;margin-top:0px;font-size:24px;@media (min-width: 768px){margin-bottom:48px;}"},V={name:"1b5xezq",styles:"margin-bottom:24px;margin-top:0px;font-family:var(--font-primary);font-weight:700;line-height:30px;font-size:24px"},L={name:"q3lk3d",styles:"--tw-text-opacity:1;color:rgb(25 173 238 / var(--tw-text-opacity, 1))"},W={name:"r95238",styles:"margin-bottom:0px;font-size:18px;line-height:1.375;transition-property:all;transition-timing-function:cubic-bezier(0.4, 0, 0.2, 1);transition-duration:300ms"},y={name:"1p5cpq7",styles:"margin-bottom:24px !important"};i.default=A=>{var i;return(0,n.FD)(o.PE,{noTray:!0,children:[(0,n.Y)(o.kW,{title:"NERLYNX® (neratinib) tablets | Important Safety Information",description:"Important Safety Information | NERLYNX® (neratinib) tablets is indicated for the treatment of early-stage HER2+ breast cancer following adjuvant trastuzumab-based therapy and metastatic HER2+ breast cancer in combination with capecitabine following two or more prior anti-HER2 based regimens in the metastatic setting. See recurrence and progression rates data. Please see important safety information and full Prescribing Information.",path:null===(i=A.location)||void 0===i?void 0:i.pathname}),(0,n.Y)(o.lq,{backgroundImage:a.A,headlinePadding:"right",backgroundStyle:{backgroundSize:"cover",backgroundRepeat:"no-repeat",backgroundPosition:"85%",width:"101%"},titleStyle:{marginTop:"-1rem",marginBottom:"20px","@media (min-width: 768px)":{marginTop:"0px",marginBottom:"0px"}},halfHeight:!0,children:"Important Safety Information"}),(0,n.FD)(o.Fe,{css:s,children:[(0,n.Y)(o.H2,{blue:!0,css:I,children:"Warnings and Pre

1cautions"}),(0,n.FD)(o.IP,{css:g,children:[(0,n.FD)("li",{css:l,children:[(0,n.FD)("strong",{children:[(0,n.Y)(o.D,{cap:!0}),":"]})," Manage diarrhea through either NERLYNX dose escalation or loperamide prophylaxis. If diarrhea occurs despite recommended prophylaxis, treat with additional antidiarrheals, fluids, and electrolytes as clinically indicated. Withhold NERLYNX in patients experiencing severe and/or persistent diarrhea. Permanently discontinue NERLYNX in patients experiencing Grade 4 diarrhea or Grade ≥2 diarrhea that occurs after maximal dose reduction."]}),(0,n.FD)("li",{css:r,children:[(0,n.Y)("strong",{children:"Hepatotoxicity:"})," Monitor liver function tests monthly for the first 3 months of treatment, then every 3 months while on treatment and as clinically indicated. Withhold NERLYNX in patients experiencing Grade 3 liver abnormalities and permanently discontinue NERLYNX in patients experiencing Grade 4 liver abnormalities. Embryo-Fetal Toxicity: NERLYNX can cause fetal harm. Advise patients of potential risk to a fetus and to use effective contraception."]}),(0,n.FD)("li",{children:[(0,n.Y)("strong",{children:"Embryo-Fetal Toxicity:"})," ",(0,n.Y)(o.z_,{})," can cause fetal harm. Advise patients of potential risk to a fetus and to use effective contraception."]})]}),(0,n.FD)(o.H2,{blue:!0,css:C,children:[(0,n.Y)("strong",{css:E,children:"ADVERSE REACTIONS:"})," The most common adverse reactions (reported in ≥5% of patients) were:"]}),(0,n.FD)(o.IP,{css:p,children:[(0,n.FD)("li",{css:Q,children:[(0,n.Y)(o.z_,{})," as a single agent: ",(0,n.Y)(o.D,{}),", nausea, abdominal pain, fatigue, vomiting, rash, stomatitis, decreased appetite, muscle spasms, dyspepsia, AST or ALT increased, nail disorder, dry skin, abdominal distention, epistaxis, weight decreased, and urinary tract infection."]}),(0,n.FD)("li",{children:[(0,n.Y)(o.z_,{})," in combination with capecitabine: ",(0,n.Y)(o.D,{}),", nausea, vomiting, decreased appetite, constipation, fatigue/asthenia, weight decreased, dizziness, back pain, arthralgia, urinary tract infection, upper respiratory tract infection, abdominal distention, renal impairment, and muscle spasms."]})]}),(0,n.Y)(o.P,{css:S,blue:!0,children:(0,n.FD)("strong",{children:["To report ",(0,n.Y)(o.ri,{children:"suspected adverse reactions"}),", contact Puma Biotechnology, Inc. at 1-844-",(0,n.Y)(o.z_,{})," (",(0,n.Y)(e.v,{phoneNumber:"1-844-637-5969"}),") or FDA at"," ",(0,n.Y)(e.v,{phoneText:"1-800-FDA-1088",phoneNumber:"1-800-332-1088"})," ","or ",(0,n.Y)("em",{children:"www.fda.gov/medwatch"}),"."]})}),(0,n.Y)(o.H2,{css:m,children:(0,n.Y)(o.ri,{css:q,blue:!0,children:"Drug Interactions:"})}),(0,n.FD)(o.IP,{css:K,children:[(0,n.FD)("li",{css:F,children:["Gastric acid reducing agents: Avoid concomitant use with proton pump inhibitors. Separate ",(0,n.Y)(o.z_,{})," by at least 2 hours before or 10 hours after H",(0,n.Y)("sub",{children:"2"}),"-receptor antagonists. Or separate"," ",(0,n.Y)(o.z_,{})," by at least 3 hours after antacids."]}),(0,n.Y)("li",{css:c,children:"Strong CYP3A4 inhibitors: Avoid concomitant use."}),(0,n.Y)("li",{css:U,children:"P-gp and moderate CYP3A4 dual inhibitors: Avoid concomitant use."}),(0,n.Y)("li",{css:B,children:"Strong or moderate CYP3A4 inducers: Avoid concomitant use."}),(0,n.FD)("li",{css:J,children:["Certain P-gp substrates: Monitor for adverse reactions of P-gp substrates for which minimal concentration change may lead to serious adverse reactions when used concomitantly with ",(0,n.Y)(o.z_,{}),"."]})]}),(0,n.Y)(o.H2,{blue:!0,css:h,children:"Use In Specific Populations:"}),(0,n.Y)(o.IP,{css:d,children:(0,n.FD)("li",{children:[(0,n.Y)("strong",{children:"Lactation:"})," Advise women not to breastfeed."]})}),(0,n.Y)(o.P,{css:k,children:(0,n.FD)("strong",{children:["Please see"," ",(0,n.Y)(o.rF,{to:"/pdf/full-prescribing-information.pdf",customCss:{textDecorationLine:"none"},children:"Full Prescribing Information"}),"."]})}),(0,n.FD)(o.H2,{id:"indications",blue:!0,css:V,children:[(0,n.Y)("span",{css:L,children:"INDICATIONS:"})," NERLYNX® (neratinib) tablets, for oral use, is a kinase inhibitor indicated:"]}),(0,n.FD)(o.IP,{css:W,children:[(0,n.Y)("li",{css:y,children:"As a single agent, for the extended adjuvant treatment of adult patients with early-stage HER2-positive breast cancer, to follow adjuvant trastuzumab-based therapy."}),(0,n.Y)("li",{children:"In combination with capecitabine, for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer who have received t

1wo or more prior anti-HER2 based regimens in the metastatic setting."})]})]})]})}},7604:function(A,i){i.A="data:image/jpeg;base64,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"}}]);
2//# sourceMappingURL=component---src-pages-isi-tsx-a3c019a76dd14790a009.js.map